AcquisitionJul 20, 2026Pending
🇺🇸 United States
PPersonalis, Inc.TATempus AI, Inc.
Healthcare › Life Science Tools & Diagnostics
Deal valueUndisclosed
AnnouncedJul 20, 2026
ConsiderationStock
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Tempus AI, Inc. agreed to acquire Personalis, Inc. through a two-step merger in which each outstanding share of Personalis common stock converts into shares of Tempus Class A common stock at an exchange ratio of 0.3356 (if the Tempus stock price is at or below $48.42) or $16.25 divided by the Tempus stock price, with Tempus permitted to elect to pay $16.25 per share in cash for up to 50% of the outstanding Personalis shares.
Deal rationale
The document presents the combination as reflecting the strategic logic of combining Tempus and Personalis, whose cancer genomic testing and sequencing capabilities complement Tempus' diagnostics and data platform.
AI-generated from the SEC filingPendingHealthcare › Life Science Tools & DiagnosticsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
MSMorgan Stanley
Sell-side
CPCenterview PartnersTSTD Securities
Parties
Target
PPersonalis, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
TATempus AI, Inc.
- Headquarters
- United States
- Ticker
- —